The effect of erythropoietin in reduction of tissue–reperfusion injury after coronary artery baypass graft
Not Applicable
- Conditions
- Tissue-reperfusiuon injury.Atherosclerotic heart disease
- Registration Number
- IRCT138809102799N1
- Lead Sponsor
- Deputy of Research and Technology of Mazandarn University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
sign of angina pectoris need to revascularization after angiography, presence of indication for CABG
Exclusion criteria: history of Myocardial Infarction since 3 months prior to the study, EF<30%, history of streptokinase taking, hemoglobin >16 , Cr > 2.5, receiving Erythropoietin since 6 months prior to the study, blood pressure > 150/95, history of Arterial fibrillation blood transfusion since 3 months prior to the study, heavy or cardiac trauma since 3 months prior to the study, polycytemia vera
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cardiac function (Wall Motion Score Index). Timepoint: 4 days, 30 days. Method of measurement: echocardiography.;Cardiac function (Ejection Fraction). Timepoint: Before surgery, 4 days and 30 days after surgery. Method of measurement: echocardiography.
- Secondary Outcome Measures
Name Time Method Cardiac marker (CKMB). Timepoint: Before and 10 hours after surgery. Method of measurement: labratory.;Cardiac marker (Troponin I). Timepoint: Before and 10 hours after surgery. Method of measurement: labratory.